Groundbreaking Disease Testing Platform Brings Laboratory in Palm of the Hand

GRIP Molecular Technologies (Saint Paul, MN, USA) is pioneering this shift with its advanced electronic biosensor technology. This innovation promises to deliver laboratory-grade, multi-disease diagnostic results directly to consumers within minutes. Utilizing self-obtained samples, the platform employs a disposable diagnostic cartridge that interfaces with a standard smartphone, displaying results and enabling secure transmission to the user's healthcare provider. This facilitates a data-driven telehealth interaction, enabling rapid disease diagnosis and swift initiation of the appropriate treatment, all virtually. GRIP's approach revolutionizes diagnostics by substituting traditional chemical assays with sophisticated graphene-based and dielectrophoresis-enhanced solid-state electronics. This method addresses the fundamental limitations of current chemistry-based diagnostics, providing crucial medical diagnostic information at the critical point of need — whether at home, in eldercare facilities, or at retail pharmacies.

The technology is capable of delivering actionable diagnostic information for multiple diseases swiftly with a single test, empowering both patients and physicians with the data necessary to make informed, quick therapy decisions, often circumventing the need for a clinic visit. Designed for convenience, GRIP's system can be used in various settings like homes, eldercare facilities, or pharmacies, and requires just a single saliva sample to detect multiple diseases. The biosensor then wirelessly communicates the data to a standard mobile device for display. No electric cables or separate readers are needed. With a simple press, the test results can be securely transmitted to a healthcare provider, facilitating either virtual telehealth consultations or informed in-clinic interactions.

"Imagine the power of a centralized medical laboratory in the palm of your hand ready to provide diagnostic information within minutes, anytime, anywhere. Our novel biosensor technology is poised to make this a reality,” said Bruce Batten, PhD, GRIP's Founder and Chief Technology Officer.

Related Links:
GRIP Molecular Technologies